JP2015514778A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015514778A5 JP2015514778A5 JP2015507173A JP2015507173A JP2015514778A5 JP 2015514778 A5 JP2015514778 A5 JP 2015514778A5 JP 2015507173 A JP2015507173 A JP 2015507173A JP 2015507173 A JP2015507173 A JP 2015507173A JP 2015514778 A5 JP2015514778 A5 JP 2015514778A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- composition
- smad7
- antisense oligonucleotide
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261625904P | 2012-04-18 | 2012-04-18 | |
| US61/625,904 | 2012-04-18 | ||
| PCT/US2013/037150 WO2013158868A1 (en) | 2012-04-18 | 2013-04-18 | Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018104372A Division JP2018131468A (ja) | 2012-04-18 | 2018-05-31 | 糖尿病を処置する方法および／または移植後の膵島の生存を促進する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015514778A JP2015514778A (ja) | 2015-05-21 |
| JP2015514778A5 true JP2015514778A5 (enExample) | 2016-06-09 |
| JP6348484B2 JP6348484B2 (ja) | 2018-06-27 |
Family
ID=48326412
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015507173A Expired - Fee Related JP6348484B2 (ja) | 2012-04-18 | 2013-04-18 | 糖尿病を処置する方法および／または移植後の膵島の生存を促進する方法 |
| JP2018104372A Pending JP2018131468A (ja) | 2012-04-18 | 2018-05-31 | 糖尿病を処置する方法および／または移植後の膵島の生存を促進する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018104372A Pending JP2018131468A (ja) | 2012-04-18 | 2018-05-31 | 糖尿病を処置する方法および／または移植後の膵島の生存を促進する方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10081809B2 (enExample) |
| EP (1) | EP2839004B1 (enExample) |
| JP (2) | JP6348484B2 (enExample) |
| KR (1) | KR20150003824A (enExample) |
| CN (2) | CN107252492A (enExample) |
| AU (1) | AU2013249191B2 (enExample) |
| CA (1) | CA2870547A1 (enExample) |
| DK (1) | DK2839004T3 (enExample) |
| ES (1) | ES2732252T3 (enExample) |
| IN (1) | IN2014DN08158A (enExample) |
| MX (1) | MX370149B (enExample) |
| NZ (1) | NZ630914A (enExample) |
| RU (1) | RU2667960C2 (enExample) |
| WO (1) | WO2013158868A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| RU2593939C2 (ru) | 2008-11-13 | 2016-08-10 | Ногра Фарма Лимитед | Антисмысловые композиции и способы их получения и применения |
| JP6389122B2 (ja) | 2011-09-15 | 2018-09-12 | ノグラ ファーマ リミテッド | 抗ｓｍａｄ７治療に対する応答性をモニターするための方法 |
| MX370149B (es) | 2012-04-18 | 2019-12-03 | Nogra Pharma Ltd | Inhibidores de la expresión o función de smad7 para usarse en el tratamiento de diabetes y/o la promoción de la supervivencia de islotes pancreáticos después del trasplante. |
| US10006029B2 (en) | 2013-03-15 | 2018-06-26 | Nogra Pharma Limited | Methods of treating colorectal cancer |
| EP2940115B1 (en) * | 2014-04-30 | 2018-10-17 | The Procter and Gamble Company | Cleaning composition |
| CA2948411A1 (en) | 2014-05-09 | 2015-11-12 | Nogra Pharma Limited | Methods for treating inflammatory bowel disease |
| US10337004B2 (en) | 2014-10-17 | 2019-07-02 | Nogra Pharma Limited | Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide |
| ES2718380T3 (es) * | 2015-10-29 | 2019-07-01 | Procter & Gamble | Composición detergente líquida |
| EP3162878A1 (en) * | 2015-10-29 | 2017-05-03 | The Procter and Gamble Company | Liquid detergent composition |
| US11162097B2 (en) | 2016-02-23 | 2021-11-02 | Nogra Pharma Limited | Methods of treating intestinal fibrosis using SMAD7 inhibition |
| WO2019217571A1 (en) * | 2018-05-08 | 2019-11-14 | University Of Miami | Materials and methods for the delivery of therapeutic nucleic acids to tissues |
| BR112021022682A2 (pt) | 2019-05-14 | 2022-02-22 | Provention Bio Inc | Métodos e composições para prevenir diabetes do tipo 1 |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| WO2022251253A1 (en) | 2021-05-24 | 2022-12-01 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| EP1456380B1 (en) | 2001-11-02 | 2012-04-18 | Giuliani International Limited | Smad7 inhibitors for the treatment of cns diseases |
| ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| WO2005014782A2 (en) | 2003-06-13 | 2005-02-17 | Alnylam Europe Ag., | Double-stranded ribonucleic acid with increased effectiveness in an organism |
| ITRM20030393A1 (it) * | 2003-08-11 | 2005-02-12 | Giuliani Spa | Uso di oligonucleotidi (odn) antisenso per smad7 per il trattamento delle patologie mediate dal fattore di trascrizione nucleare nf-kb. |
| GB0326778D0 (en) | 2003-11-18 | 2003-12-24 | Imp College Innovations Ltd | Biological materials and uses thereof |
| AU2005288522B2 (en) | 2004-09-28 | 2012-06-28 | Quark Pharmaceuticals, Inc. | Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases |
| RU2434942C2 (ru) * | 2004-09-28 | 2011-11-27 | Кварк Фармасьютикалс, Инк. | Олигорибонуклеотиды и способы их применения для лечения острой почечной недостаточности и других заболеваний |
| WO2007039151A1 (en) | 2005-09-28 | 2007-04-12 | Universität Zürich | Blockers of transforming growth factor beta and its receptors for the treatment of infectious diseases |
| DK2281042T3 (en) | 2008-04-18 | 2015-11-09 | Baxter Int | Microsphere-based composition for preventing and / or deletion of starting autoimmune diabetes |
| RU2593939C2 (ru) * | 2008-11-13 | 2016-08-10 | Ногра Фарма Лимитед | Антисмысловые композиции и способы их получения и применения |
| JP6389122B2 (ja) | 2011-09-15 | 2018-09-12 | ノグラ ファーマ リミテッド | 抗ｓｍａｄ７治療に対する応答性をモニターするための方法 |
| MX370149B (es) | 2012-04-18 | 2019-12-03 | Nogra Pharma Ltd | Inhibidores de la expresión o función de smad7 para usarse en el tratamiento de diabetes y/o la promoción de la supervivencia de islotes pancreáticos después del trasplante. |
| US10006029B2 (en) | 2013-03-15 | 2018-06-26 | Nogra Pharma Limited | Methods of treating colorectal cancer |
| CN105008394B (zh) | 2013-03-15 | 2021-10-22 | 诺格尔制药有限公司 | 治疗结肠直肠癌的方法 |
| CA2948411A1 (en) | 2014-05-09 | 2015-11-12 | Nogra Pharma Limited | Methods for treating inflammatory bowel disease |
| US10337004B2 (en) | 2014-10-17 | 2019-07-02 | Nogra Pharma Limited | Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide |
| EP3213070A2 (en) | 2014-10-17 | 2017-09-06 | Nogra Pharma Limited | Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels |
| JP2018531936A (ja) | 2015-09-30 | 2018-11-01 | ノグラ ファーマ リミテッド | バイオマーカー発現に基づいてｓｍａｄ７アンチセンスオリゴヌクレオチドを使用する方法 |
| CA3014383A1 (en) | 2016-02-24 | 2017-08-31 | Nogra Pharma Limited | Methods of treating celiac disease using smad7 inhibition |
| US20190328770A1 (en) | 2016-12-30 | 2019-10-31 | Nogra Pharma Limited | Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis |
-
2013
- 2013-04-18 MX MX2014012650A patent/MX370149B/es active IP Right Grant
- 2013-04-18 KR KR1020147032172A patent/KR20150003824A/ko not_active Abandoned
- 2013-04-18 NZ NZ630914A patent/NZ630914A/en not_active IP Right Cessation
- 2013-04-18 WO PCT/US2013/037150 patent/WO2013158868A1/en not_active Ceased
- 2013-04-18 IN IN8158DEN2014 patent/IN2014DN08158A/en unknown
- 2013-04-18 EP EP13721452.4A patent/EP2839004B1/en active Active
- 2013-04-18 DK DK13721452.4T patent/DK2839004T3/da active
- 2013-04-18 JP JP2015507173A patent/JP6348484B2/ja not_active Expired - Fee Related
- 2013-04-18 CA CA2870547A patent/CA2870547A1/en not_active Abandoned
- 2013-04-18 RU RU2014146170A patent/RU2667960C2/ru not_active IP Right Cessation
- 2013-04-18 CN CN201710440085.9A patent/CN107252492A/zh active Pending
- 2013-04-18 US US14/394,999 patent/US10081809B2/en not_active Expired - Fee Related
- 2013-04-18 ES ES13721452T patent/ES2732252T3/es active Active
- 2013-04-18 CN CN201380020520.2A patent/CN104487574B/zh not_active Expired - Fee Related
- 2013-04-18 AU AU2013249191A patent/AU2013249191B2/en not_active Ceased
-
2018
- 2018-05-31 JP JP2018104372A patent/JP2018131468A/ja active Pending
- 2018-08-10 US US16/100,906 patent/US10443056B2/en not_active Expired - Fee Related
-
2019
- 2019-09-04 US US16/559,974 patent/US20200239884A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014146170A (ru) | Способы лечения диабета и/или улучшения выживания панкреатических островков после трансплантации | |
| WO2009001359A3 (en) | Compositions and methods for inhibiting expression of pro-apoptotic genes | |
| JP2015511821A5 (enExample) | ||
| MX381987B (es) | El uso de un agente inhibidor de masp-2 para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2 | |
| GB2491328A (en) | Immediate/delayed drug delivery | |
| MX359548B (es) | Agentes de iarn modificados. | |
| WO2009090639A3 (en) | Sirna compounds and methods of use thereof | |
| AR084319A1 (es) | INHIBIDORES DE microARN (miARN O miR) QUE COMPRENDEN NUCLEOTIDOS BLOQUEADOS | |
| MX366119B (es) | Uso de un agente inhibidor de masp-2 para el tratamiento de condiciones renales mediadas por complemento dependiente de la masp-2. | |
| CR11723A (es) | Agente para tratar enfermedad | |
| GB2491327A (en) | Delayed prolonged drug delivery | |
| MX373926B (es) | Metodos para tratar cancer y estados no neoplasicos. | |
| PH12013500919B1 (en) | Vasoprotective and cardioprotective antidiabetic therapy | |
| JP2014501492A5 (enExample) | ||
| JP2012514021A5 (enExample) | ||
| JP2016517401A5 (enExample) | ||
| BR112014032239A2 (pt) | inibidores da família de mir-15 de micro-rnas | |
| JP2014504857A5 (enExample) | ||
| RU2015140572A (ru) | Способы лечения колоректального рака | |
| JP2012516879A5 (enExample) | ||
| WO2011153458A3 (en) | Compositions and methods for inhibition of or treatment of dengue virus infection | |
| MX348555B (es) | Agente preventivo o terapeutico contra la fibrosis. | |
| MX2014006662A (es) | Direccionamiento de en2, pax2, y/o defb1 para tratamiento de afecciones de la próstata. | |
| MX342020B (es) | Apolipoproteina a-iv como un peptido antidiabetico. | |
| JP2013520447A5 (enExample) |